LFWD

Lifeward Ltd. (LFWD) 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2024. Lifeward Ltd. (formerly ReWalk Robotics Ltd.) is a medical device company focused on physical rehabilitation and recovery. The company rebranded to Lifeward in September 2024 to reflect an expanded mission beyond its core spinal cord injury (SCI) products. Key product lines include the ReWalk Personal Exoskeleton, AlterG Anti-Gravity systems (acquired in August 2023), ReStore Exo-Suit, and MyoCycle FES cycles. The company operates primarily in the United States and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 85% year-over-year, driven by the full-year impact of the AlterG acquisition ($7.9 million contribution) and increased ReWalk sales due to new Medicare coverage pathways ($3.9 million contribution).
• Impairment Charges: The company recorded a non-cash impairment charge of $9.8 million in 2024 related to acquired intangible assets (customer relationships, technology, and trademarks) due to lower-than-expected financial performance. No such charge was recorded in 2023.
• Operating Expenses: General and Administrative (G&A) expenses decreased 48% to $5.2 million, primarily due to a $2.6 million remeasurement gain on the AlterG earn-out liability and reduced M&A costs. Sales and Marketing expenses increased 29% to $17.9 million due to higher headcount and promotional activities.
• Liquidity: Cash reserves declined significantly from $28.1 million to $6.7 million due to operating losses and working capital investments.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management and auditors have concluded there is substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company has an accumulated deficit of $264.8 million and requires additional financing to meet obligations.
• Recent Capital Raise: In January 2025, the company completed a registered direct offering raising approximately $5.0 million (gross proceeds) to fund commercial efforts and working capital.
• Strategic Streamlining: The company closed its Fremont, California facility and reduced U.S. headcount by 35% since the AlterG acquisition. These actions are expected to save approximately $3 million in operating expenses and improve gross margins by ~2 percentage points.
• Reimbursement Milestones: CMS established a Medicare reimbursement rate of $91,032 for personal exoskeletons (HCPCS code K1007) effective April 2024. The company is aggressively targeting this market. In Germany, a formal reimbursement agreement with BARMER was finalized in February 2025.
• Key Risks:
  • Dependence on third-party payors for reimbursement.
  • Geopolitical instability in Israel (where R&D and ReWalk manufacturing are located) and Taiwan (AlterG components).
  • Need for continued capital raises, which may result in shareholder dilution.
  • Failure to realize anticipated synergies from the AlterG acquisition.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.7 million year-end cash balance plus the $5.0 million raised in January 2025 against the current burn rate and the "substantial doubt" going concern warning.
• Medicare Claims Volume: Monitor the actual volume of approved Medicare claims and collections to validate the revenue growth attributed to the new reimbursement pathway.
• Cost Reduction Execution: Track the realization of the projected $3 million in operating expense savings from the U.S. streamlining and facility closures.
• Equity Plan Status: Note that the 2014 Equity Incentive Plan expired in August 2024, and a new plan has not yet been approved by shareholders, potentially impacting the ability to grant equity compensation to retain key personnel.
• Geopolitical Exposure: Assess the impact of ongoing conflicts in the Middle East on the company's Israeli operations and supply chain.